Corvus Pharmaceuticals Earnings Reports

Corvus Pharmaceuticals posted a net loss of $12.1 million in Q4 2024, driven by higher R&D spending and changes in warrant liabilities. The company ended the quarter with $52 million in cash, funding operations into Q1 2026, while continuing to progress key clinical programs.

Corvus Pharmaceuticals reported a net loss of $40.2 million for the third quarter ended September 30, 2024, compared to a net loss of $6.0 million for the same period in 2023. As of September 30, 2024, Corvus had cash, cash equivalents and marketable securities of $41.7 million compared to $27.1 million as of December 31, 2023. The company expects its cash to fund operations into 2026.

Corvus Pharmaceuticals reported a net loss of $4.3 million for the second quarter of 2024, and had cash, cash equivalents and marketable securities of $47.2 million as of June 30, 2024. The company expects its cash to fund operations into the fourth quarter of 2025.

Corvus Pharmaceuticals reported a net loss of $5.7 million for the first quarter ended March 31, 2024. The company's cash, cash equivalents, and marketable securities totaled $22.1 million as of March 31, 2024, which does not include the $30.6 million from a financing completed on May 6, 2024.

Corvus Pharmaceuticals reported a net loss of $6.7 million for the fourth quarter of 2023, compared to a net loss of $9.8 million for the same period in 2022. The company's cash, cash equivalents, and marketable securities totaled $27.1 million as of December 31, 2023.

Corvus Pharmaceuticals reported a net loss of $6.0 million for the third quarter ended September 30, 2023, compared to a net loss of $14.8 million for the same period in 2022. As of September 30, 2023, Corvus had cash, cash equivalents and marketable securities of $32.2 million.

Corvus Pharmaceuticals reported a net loss of $6.5 million for the second quarter of 2023, with cash, cash equivalents, and marketable securities totaling $37.0 million as of June 30, 2023. The company anticipates its cash will fund operations into the second half of 2024.

Corvus Pharmaceuticals reported a net loss of $7.9 million for the quarter ended March 31, 2023, compared to a net loss of $8.3 million for the same period in 2022. The company's cash, cash equivalents, and marketable securities totaled $34.5 million as of March 31, 2023. They expect full year 2023 net cash used in operating activities to be between approximately $19 million and $22 million.

Corvus Pharmaceuticals reported its Q4 and full year 2022 financial results, highlighting the progress of CPI-818 and its potential across cancer and immune diseases. The company's cash balance was $42.3 million as of December 31, 2022, and anticipates funding operations into 2024.

Corvus Pharmaceuticals reported its Q3 2022 financial results, with a net loss of $14.8 million. The company had $49.6 million in cash, cash equivalents, and marketable securities as of September 30, 2022, and anticipates several milestones for its clinical programs.

Corvus Pharmaceuticals reported a net loss of $8.4 million for the second quarter ended June 30, 2022, compared to a net loss of $11.8 million for the same period in 2021. As of June 30, 2022, Corvus had cash, cash equivalents and marketable securities totaling $56.7 million and expects its cash to fund operations into early 2024.

Corvus Pharmaceuticals reported a net loss of $8.3 million for the first quarter of 2022, compared to a net loss of $11.6 million for the same period in 2021. As of March 31, 2022, the company had cash, cash equivalents, and marketable securities totaling $62.9 million.

Corvus Pharmaceuticals reported a net loss of $9.2 million for the fourth quarter of 2021, with research and development expenses totaling $4.8 million. As of December 31, 2021, the company's cash, cash equivalents, and marketable securities amounted to $69.5 million.

Corvus Pharmaceuticals reported a net loss of $10.7 million for the third quarter ended September 30, 2021, compared to a net loss of $9.8 million for the same period in 2020. As of September 30, 2021, the company had cash, cash equivalents, and marketable securities totaling $76.3 million.

Corvus Pharmaceuticals reported a net loss of $11.8 million for the second quarter ended June 30, 2021. As of June 30, 2021, Corvus had cash, cash equivalents and marketable securities totaling $66.5 million.

Corvus Pharmaceuticals reported a net loss of $11.6 million for the first quarter ended March 31, 2021, and had cash, cash equivalents and marketable securities totaling $68.0 million as of the same date. The company is advancing its clinical programs, including a Phase 3 study of CPI-006 for COVID-19 and a Phase 2 study of CPI-818 for T cell lymphoma in partnership with Angel Pharmaceuticals.

Corvus Pharmaceuticals reported a net income of $27.1 million for the fourth quarter of 2020, with cash, cash equivalents, and marketable securities totaling $44.3 million as of December 31, 2020. The company is focused on advancing its clinical programs, including a Phase 3 study of CPI-006 for COVID-19.

Corvus Pharmaceuticals reported a net loss of $9.8 million for the third quarter ended September 30, 2020, and had cash, cash equivalents and marketable securities totaling $51.4 million at the end of the quarter.

Corvus Pharmaceuticals reported a net loss of $10.6 million for the second quarter of 2020, compared to a net loss of $13.0 million for the same period in 2019. The company's cash, cash equivalents, and marketable securities totaled $59.3 million as of June 30, 2020.

Corvus Pharmaceuticals reported a net loss of $12.9 million for the first quarter ended March 31, 2020, and had cash, cash equivalents and marketable securities totaling $68.7 million at March 31, 2020.

Corvus Pharmaceuticals reported a net loss of $11.0 million for the fourth quarter of 2019, with research and development expenses totaling $8.9 million. The company's cash, cash equivalents, and marketable securities amounted to $78.0 million as of December 31, 2019.